PF614
Phase 3Small molecule
PF614 is one of 22 small molecule programs targeting Acute Postoperative Pain. It is currently in Phase 3.
2
Indications
8
Total Trials
2
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
25 competitors in Single Dose
#DrugCompanyPhaseTrials
1Namenda
AbbViePhase 2
Lioresal
NovartisPhase 2
Daliresp
AstraZenecaPhase 2
Cialis
Eli LillyPhase 1
Opdivo
Bristol-Myers SquibbPhase 1
PF614
EEnsysce Biosciences
Phase 3
Acoziborole
DDrugs for Neglected Diseases
Phase 3
LP-003
LLongbio Pharma
Phase 2
Psilocybin
COMPASS PathwaysPhase 1
Avodart
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Abuse Potential2 trials
Oxycodone1 trial
Single Dose1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF614. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEnsysce Biosciences